independent-director-david-ramsay-just-bought-a-handful-of-shares-in-la-jolla-pharmaceutical-company-(nasdaq:ljpc)

Independent Director David Ramsay Just Bought A Handful Of Shares In La Jolla Pharmaceutical Company (NASDAQ:LJPC)

View photos

NASDAQ:LJPC) shareholders may wish to note that the Independent Director, David Ramsay, recently bought US$187k worth of stock, paying US$3.99 for each share. However, it only increased shareholding by a small percentage, and it wasn’t a huge purchase by absolute value, either.” data-reactid=”28″ type=”text”>Potential La Jolla Pharmaceutical Company (NASDAQ:LJPC) shareholders may wish to note that the Independent Director, David Ramsay, recently bought US$187k worth of stock, paying US$3.99 for each share. However, it only increased shareholding by a small percentage, and it wasn’t a huge purchase by absolute value, either.

View our latest analysis for La Jolla Pharmaceutical ” data-reactid=”29″ type=”text”> View our latest analysis for La Jolla Pharmaceutical

The Last 12 Months Of Insider Transactions At La Jolla Pharmaceutical

In fact, the recent purchase by David Ramsay was the biggest purchase of La Jolla Pharmaceutical shares made by an insider individual in the last twelve months, according to our records. That means that an insider was happy to buy shares at above the current price of US$3.77. It’s very possible they regret the purchase, but it’s more likely they are bullish about the company. To us, it’s very important to consider the price insiders pay for shares is very important. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.

La Jolla Pharmaceutical insiders may have bought shares in the last year, but they didn’t sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume

list of growing companies with recent insider purchasing, could be just the ticket.” data-reactid=”49″ type=”text”>La Jolla Pharmaceutical is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that La Jolla Pharmaceutical insiders own 6.0% of the company, worth about US$6.2m. Whilst better than nothing, we’re not overly impressed by these holdings.

So What Does This Data Suggest About La Jolla Pharmaceutical Insiders?

1 warning sign for La Jolla Pharmaceutical and we suggest you have a look.” data-reactid=”53″ type=”text”>The recent insider purchase is heartening. And the longer term insider transactions also give us confidence. However, we note that the company didn’t make a profit over the last twelve months, which makes us cautious. While the overall levels of insider ownership are below what we’d like to see, the history of transactions imply that La Jolla Pharmaceutical insiders are reasonably well aligned, and optimistic for the future. So while it’s helpful to know what insiders are doing in terms of buying or selling, it’s also helpful to know the risks that a particular company is facing. You’d be interested to know, that we found 1 warning sign for La Jolla Pharmaceutical and we suggest you have a look.

list of interesting companies with high ROE and low debt.” data-reactid=”54″ type=”text”>But note: La Jolla Pharmaceutical may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected].” data-reactid=”56″ type=”text”>

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected].

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top